

Mattia Novo

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9804331/publications.pdf>

Version: 2024-02-01

10
papers

72
citations

1684188

5
h-index

1588992

8
g-index

10
all docs

10
docs citations

10
times ranked

122
citing authors

#	ARTICLE	IF	CITATIONS
1	Clinical manifestations of, diagnostic approach to, and treatment of neurolymphomatosis in the rituximab era. <i>Blood Advances</i> , 2021, 5, 1379-1387.	5.2	18
2	High-grade B-cell lymphoma: how to diagnose and treat. <i>Expert Review of Hematology</i> , 2019, 12, 497-506.	2.2	15
3	Axicabtagene Ciloleucel Chimeric Antigen Receptor T Cell Therapy in Lymphoma With Secondary Central Nervous System Involvement. <i>Mayo Clinic Proceedings</i> , 2019, 94, 2361-2364.	3.0	12
4	Persistent mediastinal FDG uptake on PET-CT after frontline therapy for Hodgkin lymphoma: biopsy, treat or observe?. <i>Leukemia and Lymphoma</i> , 2020, 61, 318-327.	1.3	9
5	Aggressive Non-Hodgkin lymphomas: risk factors and treatment of central nervous system recurrence. <i>Expert Review of Hematology</i> , 2019, 12, 787-796.	2.2	7
6	MYC Rearranged Aggressive B-Cell Lymphomas: A Report on 100 Patients of the Fondazione Italiana Linfomi (FIL). <i>HemaSphere</i> , 2019, 3, e305.	2.7	4
7	Impact of hypoalbuminemia on the prognosis of relapsed/refractory B-cell lymphoma treated with axicabtagene ciloleucel. <i>European Journal of Haematology</i> , 2021, 107, 48-53.	2.2	3
8	Chemotherapy combinations for B-cell lymphoma and chemo-free approach in elderly patients: an update on best practice. <i>Expert Review of Hematology</i> , 2020, 13, 851-869.	2.2	2
9	Peak absolute lymphocyte count after CAR-T infusion predicts clinical response in aggressive lymphoma. <i>American Journal of Hematology</i> , 2022, 97, .	4.1	2
10	Intensified therapy in diffuse large B-cell lymphoma. <i>Oncotarget</i> , 2018, 9, 12548-12549.	1.8	0